Update on amyloid imaging: From healthy aging to Alzheimer's disease

Current Neurology and Neuroscience Reports

Volumn 9, Issue 5, 2009, Pages 345-352

  Wolk, David A ^a   Klunk, William E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYLOID IMAGING; BRAIN METABOLISM; CEREBELLUM; COGNITION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG BINDING; EARLY DIAGNOSIS; HUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; TISSUE LEVEL; WHITE MATTER;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; COGNITION; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS;

EID: 68449090629     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0051-4     Document Type: Review

References (51)

1. Small GW, Kepe V, Ercoli LM, et al.: PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006, 355:2652-2663.
2. Verhoeff NP, Wilson AA, Takeshita S, et al.: In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004, 12:584-595.
3. Klunk WE, Engler H, Nordberg A, et al.: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
4. Mueller SG, Weiner MW, Thal LJ, et al.: The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005, 15:869-877, xi-xii.
5. Klunk WE, Lopresti BJ, Ikonomovic MD, et al.: Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005, 25:10598-10606.
6. Klunk WE, Wang Y, Huang GF, et al.: The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003, 23:2086-2092.
7. Thal DR, Rub U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
8. Fagan AM, Mintun MA, Mach RH, et al.: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512-519.
9. Ikonomovic MD, Klunk WE, Abrahamson EE, et al.: Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
10. Bacskai BJ, Frosch MP, Freeman SH, et al.: Molecular imaging with Pittsburgh compound B confirmed at autopsy: A case report. Arch Neurol 2007, 64:431-434.
11. Leinonen V, Alafuzoff I, Aalto S, et al.: Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol 2008, 65:1304-1309.
12. Klunk WE: Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist. Arch Neurol 2008, 65:1281-1283.
13. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
14. Kemppainen NM, Aalto S, Wilson IA, et al.: PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68:1603-1606.
15. Rowe CC, Ng S, Ackermann U, et al.: Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
16. Edison P, Archer HA, Hinz R, et al.: Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology 2007, 68:501-508.
17. Jack CR Jr, Lowe VJ, Weigand SD, et al.: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132(Pt 5):1355-1365.
18. Dubois B, Feldman HH, Jacova C, et al.: Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
19. Engler H, Forsberg A, Almkvist O, et al.: Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2856-2866.
20. Klunk WE, Mathis CA, Price JC, et al.: Two-year follow-up of amyloid deposition in patients with Alzheimer's disease [commentary]. Brain 2006, 129:2805-2807.
21. Terry RD, Masliah E, Salmon DP, et al.: Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
22. DeKosky ST, Scheff SW: Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 1990, 27:457-464.
23. Stern Y, Gurland B, Tatemichi TK, et al.: Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994, 271:1004-1010.
24. Roe CM, Xiong C, Miller JP, Morris JC: Education and Alzheimer disease without dementia: Support for the cognitive reserve hypothesis. Neurology 2007, 68:223-228.
25. Bennett DA, Schneider JA, Wilson RS, et al.: Education modifies the association of amyloid but not tangles with cognitive function. Neurology 2005, 65:953-955.
26. Kemppainen NM, Aalto S, Karrasch M, et al.: Cognitive reserve hypothesis: Pittsburgh compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 2008, 63:112-118.
27. Nelissen N, Vandenbulcke M, Fannes K, et al.: Abeta amyloid deposition in the language system and how the brain responds. Brain 2007, 130:2055-2069.
28. Johansson A, Savitcheva I, Forsberg A, et al.: [(11)C]-PIB imaging in patients with Parkinson's disease: Preliminary results. Parkinsonism Relat Disord 2008, 14:345-347.
29. Maetzler W, Reimold M, Liepelt I, et al.: [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008, 39:1027-1033.
30. McKeith I, Mintzer J, Aarsland D, et al.: Dementia with Lewy bodies. Lancet Neurol 2004, 3:19-28.
31. Alladi S, Xuereb J, Bak T, et al.: Focal cortical presentations of Alzheimer's disease. Brain 2007, 130:2636-2645.
32. Rabinovici GD, Furst AJ, O'Neil JP, et al.: 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68:1205-1212.
33. Rabinovici GD, Jagust WJ, Furst AJ, et al.: Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008, 64:388-401.
34. Mesulam M, Wicklund A, Johnson N, et al.: Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008, 63:709-719.
35. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256:183-194.
36. Visser PJ, Kester A, Jolles J, Verhey F: Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006, 67:1201-1207.
37. Jicha GA, Parisi JE, Dickson DW, et al.: Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006, 63:674-681.
38. Larrieu S, Letenneur L, Orgogozo JM, et al.: Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002, 59:1594-1599.
39. Fleisher AS, Sowell BB, Taylor C, et al.: Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2007, 68:1588-1595.
40. Jack CR, Petersen RC, Xu YC, et al.: Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397-1403.
41. Hansson O, Zetterberg H, Buchhave P, et al.: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006, 5:228-234.
42. Drzezga A, Grimmer T, Riemenschneider M, et al.: Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005, 46:1625-1632.
43. Forsberg A, Engler H, Almkvist O, et al.: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008, 29:1456-1465.
44. Pike KE, Savage G, Villemagne VL, et al.: Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
45. Jack CR Jr, Lowe VJ, Senjem ML, et al.: 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
46. Wolk DA, Price JC, Saxton JA, et al.: Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009, 65:557-568.
47. Koivunen J, Pirttila T, Kemppainen N, et al.: PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008, 26:378-383.
48. Price JL, Morris JC: Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999, 45:358-368.
49. Aizenstein HJ, Nebes RD, Saxton JA, et al.: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008, 65:1509-1517.
50. Villemagne VL, Pike KE, Darby D, et al.: Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008, 46:1688-1697.
51. Dickerson BC, Bakkour A, Salat DH, et al.: The cortical signature of Alzheimer's disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009, 19:497-510.